{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-22-000085","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2022-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.772983+00:00","generated_at":"2026-06-23T08:07:26.008494+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lisata halts XOWNA FREEDOM Trial; development now contingent on partner","bullets":["Phase 2b FREEDOM Trial of XOWNA (autologous CD34+ cells) suspended May 2022 due to COVID enrollment challenges and heterogeneity.","Interim analysis of first 20 patients with 6-month follow-up completed; board decided redesigned trial is needed but prohibitively expensive alone.","XOWNA development will only continue if a strategic partner is identified and secured to fund a redesigned trial.","No assurance that a partner can be found or that acceptable terms will be reached."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-22-000085","json":"https://secwatch.observer/filing/0000320017-22-000085.json","markdown":"https://secwatch.observer/filing/0000320017-22-000085.md","text":"https://secwatch.observer/filing/0000320017-22-000085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001722000085/0000320017-22-000085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001722000085/clbs-20220922.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:07:26.008494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}